FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361010918> ?p ?o ?g. }

• W4361010918 endingPage "2188" @default.
• W4361010918 startingPage "2172" @default.
• W4361010918 abstract "Background and Purpose Neutrophilic inflammation is a critical pathogenic factor in psoriasis. The therapeutic applicability of palbociclib, a cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor clinically used to treat cancer, in the treatment of neutrophil‐associated psoriasis remains undefined. In this study, we evaluated the therapeutic potential and pharmacological effect of palbociclib on neutrophil‐associated psoriasiform dermatitis. Experimental Approach The anti‐inflammatory effects of palbociclib were determined in activated human neutrophils. The therapeutic feasibility of palbociclib in psoriasis was demonstrated in a mouse model of imiquimod‐induced psoriasiform dermatitis. The in vitro enzymatic assays and in silico analyses were used to identify the underlying pharmacological mechanisms. Key Results This study found that palbociclib inhibited neutrophilic inflammation, including superoxide anion generation, reactive oxygen species (ROS) formation, elastase degranulation and chemotactic responses. The mechanistic studies identified that the anti‐inflammatory effects of palbociclib involved the targeting of phosphatidylinositol 3‐kinase (PI3K) but not CDK4/6 in human neutrophils. Palbociclib preferentially targeted the p110δ catalytic subunit of PI3K and thereby blocked signalling via the PI3K/protein kinase B (Akt) pathway. Furthermore, topical application of palbociclib significantly ameliorated imiquimod‐induced psoriasiform dermatitis in mice, including psoriatic symptoms, neutrophil infiltration, Akt activation and cytokine up‐regulation. Conclusions and Implications This is the first study to demonstrate that palbociclib can potentially be used to treat neutrophil‐associated psoriasiform dermatitis through the targeting of neutrophilic PI3K activity. Our findings prompt further research to explore the potential of palbociclib and PI3K in psoriasis and other inflammatory diseases." @default.
• W4361010918 created "2023-03-30" @default.
• W4361010918 creator A5007693722 @default.
• W4361010918 creator A5013734423 @default.
• W4361010918 creator A5014212972 @default.
• W4361010918 creator A5034806375 @default.
• W4361010918 creator A5036094903 @default.
• W4361010918 creator A5036396991 @default.
• W4361010918 creator A5061750533 @default.
• W4361010918 creator A5062671167 @default.
• W4361010918 creator A5066359340 @default.
• W4361010918 creator A5083689040 @default.
• W4361010918 date "2023-04-19" @default.
• W4361010918 modified "2023-10-17" @default.
• W4361010918 title "Palbociclib blocks neutrophilic phosphatidylinositol 3‐kinase activity to alleviate psoriasiform dermatitis" @default.
• W4361010918 cites W1593555249 @default.
• W4361010918 cites W1658093144 @default.
• W4361010918 cites W1663045307 @default.
• W4361010918 cites W1913582086 @default.
• W4361010918 cites W1971890183 @default.
• W4361010918 cites W1984802220 @default.
• W4361010918 cites W2040252933 @default.
• W4361010918 cites W2043108620 @default.
• W4361010918 cites W2084141237 @default.
• W4361010918 cites W2085690242 @default.
• W4361010918 cites W2097637220 @default.
• W4361010918 cites W2134943518 @default.
• W4361010918 cites W2166318413 @default.
• W4361010918 cites W2196320070 @default.
• W4361010918 cites W2239012512 @default.
• W4361010918 cites W2342271048 @default.
• W4361010918 cites W2344484069 @default.
• W4361010918 cites W2399438934 @default.
• W4361010918 cites W2465174798 @default.
• W4361010918 cites W2571242354 @default.
• W4361010918 cites W2600714903 @default.
• W4361010918 cites W2606513998 @default.
• W4361010918 cites W2735134685 @default.
• W4361010918 cites W2742484040 @default.
• W4361010918 cites W2757817807 @default.
• W4361010918 cites W2766872204 @default.
• W4361010918 cites W2792530460 @default.
• W4361010918 cites W2793018823 @default.
• W4361010918 cites W2794504806 @default.
• W4361010918 cites W2797477772 @default.
• W4361010918 cites W2799372852 @default.
• W4361010918 cites W2805948893 @default.
• W4361010918 cites W2884690151 @default.
• W4361010918 cites W2890828844 @default.
• W4361010918 cites W2902459518 @default.
• W4361010918 cites W2911237943 @default.
• W4361010918 cites W2911748521 @default.
• W4361010918 cites W2914319930 @default.
• W4361010918 cites W2933816136 @default.
• W4361010918 cites W2959800828 @default.
• W4361010918 cites W2967781397 @default.
• W4361010918 cites W2980214381 @default.
• W4361010918 cites W2987868213 @default.
• W4361010918 cites W3002371404 @default.
• W4361010918 cites W3010575887 @default.
• W4361010918 cites W3020748318 @default.
• W4361010918 cites W3039634112 @default.
• W4361010918 cites W3042519295 @default.
• W4361010918 cites W3045195772 @default.
• W4361010918 cites W3048846693 @default.
• W4361010918 cites W3085242393 @default.
• W4361010918 cites W3085242789 @default.
• W4361010918 cites W3092135625 @default.
• W4361010918 cites W3094216524 @default.
• W4361010918 cites W3172554811 @default.
• W4361010918 cites W3196002498 @default.
• W4361010918 cites W3199710005 @default.
• W4361010918 cites W3203757873 @default.
• W4361010918 cites W3216061490 @default.
• W4361010918 cites W4200397744 @default.
• W4361010918 cites W4210476327 @default.
• W4361010918 cites W4213045746 @default.
• W4361010918 cites W4236357753 @default.
• W4361010918 cites W4282941439 @default.
• W4361010918 cites W4283390786 @default.
• W4361010918 doi "https://doi.org/10.1111/bph.16080" @default.
• W4361010918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36967633" @default.
• W4361010918 hasPublicationYear "2023" @default.
• W4361010918 type Work @default.
• W4361010918 citedByCount "1" @default.
• W4361010918 countsByYear W43610109182023 @default.
• W4361010918 crossrefType "journal-article" @default.
• W4361010918 hasAuthorship W4361010918A5007693722 @default.
• W4361010918 hasAuthorship W4361010918A5013734423 @default.
• W4361010918 hasAuthorship W4361010918A5014212972 @default.
• W4361010918 hasAuthorship W4361010918A5034806375 @default.
• W4361010918 hasAuthorship W4361010918A5036094903 @default.
• W4361010918 hasAuthorship W4361010918A5036396991 @default.
• W4361010918 hasAuthorship W4361010918A5061750533 @default.
• W4361010918 hasAuthorship W4361010918A5062671167 @default.
• W4361010918 hasAuthorship W4361010918A5066359340 @default.
• W4361010918 hasAuthorship W4361010918A5083689040 @default.
• W4361010918 hasConcept C121608353 @default.

• next